Department of Obstetrics and Gynaecology

A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2(-) Primary Breast Cancer (2020) Robertson JFR, Evans A, Henschen S, Kirwan CC, Jahan A, Kenny LM, Dixon JM, et al. Journal article Statement of the AGO and AG-CPC on the Aftercare/Follow-up for Surgical Procedures of the Lower Genital Tract after the Introduction of a New Cancer Screening Guideline (2020) Hillemanns P, Tempfer C, Beckmann M, Kueppers V, Quaas J Journal article Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer (2020) Huang M, O'Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey S, Briggs A, et al. Journal article Breast MRI texture analysis for prediction of BRCA-associated genetic risk (2020) Vasileiou G, Costa MJ, Long C, Wetzler I, Hoyer J, Kraus C, Popp B, et al. Journal article Erratum: SNiPER: A novel hypermethylation biomarker panel for liquid biopsy based early breast cancer detection (Oncotarget. (2019) 10 (6494-6508) DOI: 10.18632/oncotarget.27303) (2020) Mijnes J, Tiedemann J, Eschenbruch J, Gasthaus J, Bringezu S, Bauerschlag D, Maass N, et al. Journal article, Erratum Association of genomic variants at the human leukocyte antigen locus with cervical cancer risk,HPVstatus and gene expression levels (2020) Ramachandran D, Schuermann P, Mao Q, Wang Y, Bretschneider LM, Speith LM, Huelse F, et al. Journal article AXSANA (AXillary Surgery After NeoAdjuvant Treatment): A European prospective multicenter cohort study to evaluate different surgical methods of axillary staging (sentinel lymph node biopsy, targeted axillary dissection, axillary dissection) in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy (2020) Banys-Paluchowski M, Stickeler E, De Boniface J, Gentilini O, Thill M, Hartmann S, Fasching P, et al. Conference contribution DETECT III und IV - Individualisierte CTC-basierte Therapie des HER2-negativen metastasierten Mammakarzinoms (2020) Friedl TWP, Schneeweiss A, Mueller , Riethdorf S, Pantel K, Taran FA, Polasik A, et al. Conference contribution DETECT V/CHEVENDO - duale HER2-zielgerichteten Therapie mit Trastuzumab und Pertuzumab plus Ribociclib in Kombination mit Chemotherapie oder endokriner Therapie bei Patientinnen mit HER2-positivem und hormonrezeptor-positivem metastasierten Mammakarzinom (2020) Friedl TWP, Polasik A, Tzschaschel M, Schochter F, De Gregorio A, Fasching P, Taran FA, et al. Conference contribution Documentation Behavior in the CANKADO eHealth-Application and Effects on observed Side Effects - An exploratory Analysis of the PreCycle-Study (2020) Schmidt M, Degenhardt T, Fasching P, Wurstlein R, Lueftner D, Kates RE, Schumacher J, et al. Conference contribution